Business Wire

CA-PATIENT-SAFETY

4.4.2022 14:02:12 CEST | Business Wire | Press release

Share
Patient Safety Movement Foundation Announces Dates and Speaker Line-up for 8th Annual World Patient Safety, Science & Technology Summit

The Patient Safety Movement Foundation (PSMF) will host the 8th annual World Patient Safety, Science and Technology Summit (WPSSTS) virtually April 29 and April 30, 2022. The event is co-convened by the American Society of Anesthesiologists, the European Society of Anesthesiology and Intensive Care, the International Society for Quality in Health Care and the World Federation of Societies of Anaesthesiologists. Creating a powerful forum for industry leaders and healthcare organizations to confront leading patient safety issues with actionable ideas and innovations to transform the continuum of care, the event supports PSMF’s mission to reach zero preventable patient harm and death across the world by 2030.

“The last two years have been taxing on the healthcare sector to say the least. The global pandemic placed relentless stress on health systems and medical personnel, which resulted in an increase in preventable medical errors,” said Dr. Michael Ramsay, CEO of PSMF. “Our organization is eager to bring key stakeholders together to help develop solutions to dramatically improve patient safety and eliminate preventable patient harm and death.”

The summit will include a fireside chat with patient safety luminaries, seven keynote addresses, as well as five panel sessions covering various topics in patient safety led by esteemed healthcare leaders. This year’s WPSSTS sessions focus on key issues impacting the healthcare industry, including:

  • Overcoming Obstacles for Applying High Reliability Principles in Healthcare
  • Embracing the Science of Human Factors to Unleash Safety Innovation in Healthcare
  • Patient Advocacy: The Compass for Innovation
  • How Regulation Can Support Quality and Value in Healthcare
  • Healthcare Safety During the Pandemic

Attendees will have the opportunity to network with top hospital executives, patients and family members who have been impacted by medical error, public policymakers and government officials, as well as leaders across the healthcare continuum. Keynote speakers include:

  • Randall Clark, MD, FASA, president of the American Society of Anesthesiologists
  • Edoardo de Robertis, MD, PhD and president of the European Society of Anaesthesiology and Intensive Care (ESAIC)
  • Neelam Dhingra-Kumar, MD, unit head of the WHO Patient Safety Flagship
  • Carsten Engel, MD, CEO of the International Society for Quality in Health Care
  • Joe Kiani, founder & immediate past chairman of the Patient Safety Movement Foundation, as well as founder, chairman & CEO of Masimo
  • Peter Pronovost, MD, PhD, chief clinical transformation officer at University Hospitals
  • Thomas Zeltner MD, chairman of the WHO Foundation, Geneva (Switzerland) and deputy chair of the University Council of the Medical University of Vienna (Austria)

The summit is open to anyone interested in actively planning solutions around the leading patient safety challenges that cause preventable patient deaths in hospitals and healthcare organizations worldwide. Discounted registration is offered for students, patients and family members. To register for the 2022 WPSSTS or to learn more about the event, visit: https://patient.sm/WPSSTS .

About the Patient Safety Movement Foundation: The Patient Safety Movement Foundation (PSMF), a global non-profit organization founded in 2012, is celebrating 10 years of bringing awareness and creating action to eliminate preventable medical errors. Some estimates predict that one in 12 patients are impacted by a preventable medical error, but that number could be even higher as there is no central database tracking these figures in most countries, including the U.S. Over the last decade, there had been major strides to improve patient safety, but the COVID-19 pandemic stressed the system and it proved not to be resilient and took a step backwards. PSMF has a vision to eliminate preventable patient harm and death across the globe by 2030 – and that starts with raising awareness of this critical issue. It unites patients, advocates, health workers, medical technology companies, government, employers and private payers in support of this cause. From its evidence-based best practice solutions (Actionable Patient Safety Solutions™) and industry Open Data Pledge to its World Patient Safety, Science & Technology Summit and more, PSMF won’t stop fighting until it achieves zero. For more information, please visit patientsafetymovement.org , and follow PSMF on LinkedIn , Twitter , Instagram and Facebook .

Link:

ClickThru

Social Media:

https://www.facebook.com/patientsafetymovement/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Estithmar Holding Pays the Third Semi-Annual coupon of the 8.75% Sukuk Tranche12.3.2026 21:50:00 CET | Press release

Estithmar Holding Q.P.S.C. has paid the third semi-annual coupon of its Qatari Riyal-denominated Sukuk (first tranche), at an annual profit rate of 8.75%. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260312880092/en/ Estithmar Holding Pays the Third Semi-Annual coupon of the 8.75% Sukuk Tranche (Photo: AETOSWire) The first tranche, part of the company’s broader Sukuk program valued at QAR 3.4 billion and listed on the London Stock Exchange’s International Securities Market, was issued in August 2024. The issuance attracted a diverse pool of institutional investors including banks, insurance companies, and asset managers, with strong interest from both government-affiliated and private institutions. This demand reflects growing investor confidence in Estithmar Holding’s ability to deliver sustained value to stakeholders. EstithmarHolding was recently included in the FTSE Russell Global Equity Index, in Qatar’s Mid-Cap segme

Andersen Consulting styrker sine kompetencer i samarbejde med Acumen Learning12.3.2026 21:36:00 CET | Pressemeddelelse

Andersen Consulting udvider sin platform gennem en samarbejdsaftale med Acumen Learning, en amerikansk virksomhed, der specialiserer sig i træning i forretnings- og økonomiforståelse med henblik på lederudvikling og salgsresultater. Acumen Learning blev stiftet i 2002 og samarbejder med Fortune 500-virksomheder for en bedre finansiel forståelse, strategisk tænkning og beslutningstagning på alle niveauer. Med udgangspunkt i principperne fra deres bestsellerbøger "Seeing the Big Picture" og "Business Acumen for Sales Success" klæder deres programmer ledere og teams på til at afstemme beslutninger med virksomhedsstrategier, fremme resultater og styrke kunderelationer. Acumen Learning er målrettet brancher som sundhedssektoren, energi og teknologi og giver fagfolk mulighed for at omsætte forretningsviden til håndgribelige resultater. "Hos Acumen Learning er vores mission at styrke det enkelte menneske ved at skabe forretningskyndige fagfolk, der gør en forskel i deres karrierer," udtalte K

REPLY: The Board of Directors Approved the Draft Financial Statements for the Year 202512.3.2026 15:38:00 CET | Press release

All economic indicators are positive.Consolidated turnover of €2,483.6 million (€2,300.5 million in 2024);EBITDA at €467.6 million (€410.6 million in 2024);EBIT at €391.7 million (€330.4 million in 2024)Group net profit at €250.9 million (€211.1 million in 2024)Approval of the proposed dividend distribution of €1.35 per share. Today the Board of Directors of Reply S.p.A. [MTA, STAR: REY] approved the draft financial statement for the year 2025, which will be submitted for approval to the Shareholders’ Meeting to be held in first call in Turin on 23 April 2026. The Reply Group closed 2025 with a consolidated turnover of €2,483.6 million, an increase of 8.0% compared to €2,300.5 million in 2024. All indicators are positive for the period. Consolidated EBITDA was €467.6 million, an increase of 13.9% compared to €410.6 million at December 2024. EBIT, from January to December, was at €391.7 million, which is an increase of 18.5% compared to €330.4 million at December 2024. The Group net pro

LZE GmbH Introduces Fraunhofer’s RFicient® Technology to the Market12.3.2026 14:51:00 CET | Press release

LZE GmbH is expanding its technology transfer portfolio and making the RFicient® ultra-low-power wake-up receiver technology from the Fraunhofer Institute for Integrated Circuits IIS available for the first time as a standard chip for close-to-production industrial applications. The solution enables energy-efficient IoT designs that remain continuously reachable while consuming only microamps – a key step for long-lasting, low-maintenance IoT products. LZE GmbH drives technology transfer to market: standard chip availability for close-to-production applications As a bridge between research and industry, LZE GmbH is making it easier for companies to access innovative technologies and helping them to quickly and reliably transform new developments into market-ready solutions. With RFicient®-IC (FH101RF), LZE is providing another high-tech product that comes directly from Fraunhofer research and can now be ordered in volume and integrated into close-to-production product development for t

Owkin Creates New Spin out Waiv, Formerly Owkin Dx, With $33M Financing12.3.2026 14:30:00 CET | Press release

Investment lead by OTB Ventures and Alpha Intelligence CapitalWaiv develops AI-powered precision testing to better identify and stratify patients in the clinic and in clinical trials, transforming patient careWaiv extends Owkin’s strategy of real-world validation for its AI Owkin, the AI company on a mission to solve the complexity of biology, today announced the spin out of Waiv, formerly known as Owkin Dx. The move follows significant investor interest and positions Waiv to bring AI-powered precision testing for better identification of patients in the clinic and in clinical trials, to transform patient care. This follows on from the successful launch of Bioptimus, an Owkin incubated company, in February 2024. Waiv translates AI innovation into real-world clinical impact, developing tests that predict biomarkers and patient outcomes, including RlapsRisk BC for prognostic risk profiling. With multiple tests already in use in clinical settings, its deployment platform Destra, and colla

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye